Concepedia

Author

JHM Schellens

Rotterdam University of Applied Sciences

Also Known As

JHM Schellens

17

Publications

732

Citations

12

H-Index

27

Concepts

All Affiliations

Rotterdam University of Applied SciencesSlotervaartziekenhuisThe Netherlands Cancer InstituteErasmus MC Cancer InstituteUtrecht University
JS

About

JHM Schellens is an author at Rotterdam University of Applied Sciences specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

500

2

Cell Biology

2

2

208

3

Natural Sciences

1

1

26

4

Biomolecular Engineering

1

1

26

5

Biostatistics

1

1

31

JHM Schellens

×

13

Publications

583

Citations

12

H-Index

YearCitations

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

JHM Schellens, Jun Ma, A.S.T. Planting,

British Journal of Cancer

1996

146

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

JHM Schellens, G.J. Creemers, Hilde Rosing,

British Journal of Cancer

1996

130

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line

Jun Ma, Marc Maliepaard, Kees Nooter,

British Journal of Cancer

1998

62

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration

CJH Gerrits, G.J. Creemers, JHM Schellens,

British Journal of Cancer

1996

45

Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion

Jun Ma, Jaap Verweij, H. J. Kolker,

British Journal of Cancer

1994

34

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair

Jun Ma, Jaap Verweij, A.S.T. Planting,

British Journal of Cancer

1995

31

PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression

AS Zandvliet, WS Siegel-Lakhai, JH Beijnen,

Clinical Pharmacology & Therapeutics

2007

27

Dual topoisomerase I/II inhibitors

R. van Gijn, RRH Lendfers, JHM Schellens,

Journal of Oncology Pharmacy Practice

2000

26

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor

CJH Gerrits, JHM Schellens, G.J. Creemers,

British Journal of Cancer

1997

25

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours

L. Pronk, D. Schrijvers, JHM Schellens,

British Journal of Cancer

1998

20

Page 1